162 related articles for article (PubMed ID: 36542157)
1. Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [
Chan C; Prozzo V; Aghevlian S; Reilly RM
EJNMMI Radiopharm Chem; 2022 Dec; 7(1):33. PubMed ID: 36542157
[TBL] [Abstract][Full Text] [Related]
2. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
3. (111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
Costantini DL; Chan C; Cai Z; Vallis KA; Reilly RM
J Nucl Med; 2007 Aug; 48(8):1357-68. PubMed ID: 17631548
[TBL] [Abstract][Full Text] [Related]
4. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA
J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268
[TBL] [Abstract][Full Text] [Related]
5. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
[TBL] [Abstract][Full Text] [Related]
6. Assessment of Cell Cytotoxicity and Comet Assay on HER2/neu Positive Cell Line Due to
Piroozfar B; Alirezapour B; Sedeh FM; Mirzaii M; Jalilian AR; Hashemizadeh M; Raisali G
Curr Radiopharm; 2022; 15(2):148-156. PubMed ID: 34182918
[TBL] [Abstract][Full Text] [Related]
7. Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
Costantini DL; Bateman K; McLarty K; Vallis KA; Reilly RM
J Nucl Med; 2008 Sep; 49(9):1498-505. PubMed ID: 18703606
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab Labeled to High Specific Activity with (111)In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells.
Ngo Ndjock Mbong G; Lu Y; Chan C; Cai Z; Liu P; Boyle AJ; Winnik MA; Reilly RM
Mol Pharm; 2015 Jun; 12(6):1951-60. PubMed ID: 25919639
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
10. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with 111In-trastuzumab in an intraperitoneal tumor mouse model.
Keiko Li H; Hasegawa S
Nucl Med Commun; 2022 Jul; 43(7):763-769. PubMed ID: 35506286
[TBL] [Abstract][Full Text] [Related]
11. [
Kondo M; Cai Z; Chan C; Forkan N; Reilly RM
EJNMMI Radiopharm Chem; 2023 Sep; 8(1):24. PubMed ID: 37750937
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
Chan C; Fonge H; Lam K; Reilly RM
Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
[TBL] [Abstract][Full Text] [Related]
13. Kit for the preparation of
Lam K; Scollard DA; Chan C; Levine MN; Reilly RM
Appl Radiat Isot; 2015 Jan; 95():135-142. PubMed ID: 25464190
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
Costantini DL; Villani DF; Vallis KA; Reilly RM
J Nucl Med; 2010 Mar; 51(3):477-83. PubMed ID: 20150272
[TBL] [Abstract][Full Text] [Related]
15. Transcriptomic Signatures of Auger Electron Radioimmunotherapy Using Nuclear Targeting (111)In-Trastuzumab for Potential Combination Therapies.
Li HK; Morokoshi Y; Daino K; Furukawa T; Kamada T; Saga T; Hasegawa S
Cancer Biother Radiopharm; 2015 Oct; 30(8):349-58. PubMed ID: 26447839
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab labeled to high specific activity with ¹¹¹In by conjugation to G4 PAMAM dendrimers derivatized with multiple DTPA chelators exhibits increased cytotoxic potency on HER2-positive breast cancer cells.
Chan C; Cai Z; Reilly RM
Pharm Res; 2013 Aug; 30(8):1999-2009. PubMed ID: 23615858
[TBL] [Abstract][Full Text] [Related]
17.
Cai Z; Chattopadhyay N; Yang K; Kwon YL; Yook S; Pignol JP; Reilly RM
Nucl Med Biol; 2016 Dec; 43(12):818-826. PubMed ID: 27788375
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
19. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
20. 111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
Cornelissen B; Waller A; Target C; Kersemans V; Smart S; Vallis KA
EJNMMI Res; 2012 Feb; 2():9. PubMed ID: 22348532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
